These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 11436584)

  • 61. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
    Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
    J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis.
    Rodrigues ML; Costa RS; Souza CS; Foss NT; Roselino AM
    Rev Inst Med Trop Sao Paulo; 1999; 41(1):33-7. PubMed ID: 10436668
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Delayed allergic skin reactions due to intralesional meglumine antimoniate therapy for cutaneous leishmaniasis.
    Córdoba S; Gandolfo Cano M; Aguado M; Huerta-Brogera M; Romero A; Martínez-Morán C; Borbujo J
    Allergy; 2012 Dec; 67(12):1609-11. PubMed ID: 23067046
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Clinico-epidemiological study of kala-azar in the south of Madrid].
    de la Serna FJ; Salto E; Valdés D; Vos Saus R
    Rev Sanid Hig Publica (Madr); 1987; 61(7-8):783-98. PubMed ID: 3438697
    [No Abstract]   [Full Text] [Related]  

  • 65. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
    Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
    Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Treatment of localized cutaneous leishmaniasis].
    Buffet P; Caumes E; Gentilini M
    Ann Dermatol Venereol; 1994; 121(6-7):503-11. PubMed ID: 7702288
    [No Abstract]   [Full Text] [Related]  

  • 67. Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate.
    Neves DB; Caldas ED; Sampaio RN
    Trop Med Int Health; 2009 Dec; 14(12):1515-22. PubMed ID: 19954451
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol.
    Hueso M; Bover J; Serón D; Gil-Vernet S; Rufí G; Alsina J; Grinyó JM
    Nephrol Dial Transplant; 1999 Dec; 14(12):2941-3. PubMed ID: 10570102
    [No Abstract]   [Full Text] [Related]  

  • 69. Nodular lymphangitic subcutaneous dissemination after intralesional antimonial treatment for localized cutaneous leishmaniasis.
    Yébenes M; Cruz I; Cañavate C; Gilaberte M; Baena V; Pujol RM
    Clin Exp Dermatol; 2008 Mar; 33(2):142-4. PubMed ID: 18076691
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
    Krolewiecki AJ; Romero HD; Cajal SP; Abraham D; Mimori T; Matsumoto T; Juarez M; Taranto NJ
    Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R; Handjani F; Nouhpisheh MK
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Our experiences in visceral leishmaniasis therapy.
    Titone L; Scarlata F; Cascio A; Giordano S; Mancuso G
    J Chemother; 1989 Jul; 1(4 Suppl):960-1. PubMed ID: 16312722
    [No Abstract]   [Full Text] [Related]  

  • 73. [Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
    Castelló Viguer MT; Echánove Errazti I; Ridocci Soriano F; Esteban Esteban E; Atienza Fernández F; Cuesta Estellés G
    Rev Esp Cardiol; 1999 Jul; 52(7):533-5. PubMed ID: 10439681
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
    Saldanha AC; Romero GA; Merchan-Hamann E; Magalhães AV; Macedo Vde O
    Rev Soc Bras Med Trop; 1999; 32(4):383-7. PubMed ID: 10495667
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Adverse effects of intralesional Glucantime in the treatment of cutaneous leishmaniosis].
    Masmoudi A; Maalej N; Boudaya S; Turki H; Zahaf A
    Med Mal Infect; 2006 Apr; 36(4):226-8. PubMed ID: 16600554
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
    Sadeghian G; Nilfroushzadeh MA; Iraji F
    Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis.
    Lambertucci JR; França BM; Queiroz Ede M
    Rev Soc Bras Med Trop; 2004; 37(1):74-5. PubMed ID: 15042193
    [No Abstract]   [Full Text] [Related]  

  • 78. Side effects of treatment with antimony salts.
    Malta R; Affronti M; Di Rosa S; Vassallo L; Renda M; Trifirò G; Rubino ME; Rini GB
    J Chemother; 1989 Jul; 1(4 Suppl):628-9. PubMed ID: 16312564
    [No Abstract]   [Full Text] [Related]  

  • 79. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy.
    di Martino L; Mantovani MP; Gradoni L; Gramiccia M; Guandalini S
    Trans R Soc Trop Med Hyg; 1990; 84(4):534-5. PubMed ID: 2091347
    [No Abstract]   [Full Text] [Related]  

  • 80. [Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report].
    Matoussi N; Ameur HB; Amor SB; Fitouri Z; Becher SB
    Med Mal Infect; 2007 Dec; 37 Suppl 3():S257-9. PubMed ID: 18054189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.